Display options
Cite
Ozkaya A, Alkin Z, Yilmaz I, et al. Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results. Saudi J Ophthalmol. 2014;29(3):182-6doi: 10.1016/j.sjopt.2014.12.002.
Ozkaya, A., Alkin, Z., Yilmaz, I., & Yazici, A. T. (2015). Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society, 29(3), 182-6. https://doi.org/10.1016/j.sjopt.2014.12.002
Ozkaya, Abdullah, et al. "Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results." Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society vol. 29,3 (2015): 182-6. doi: https://doi.org/10.1016/j.sjopt.2014.12.002
Ozkaya A, Alkin Z, Yilmaz I, Yazici AT. Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results. Saudi J Ophthalmol. 2015 Jul-Sep;29(3):182-6. doi: 10.1016/j.sjopt.2014.12.002. Epub 2014 Dec 13. PMID: 26155075; PMCID: PMC4487941.
Copy Download .nbib Format: NLM
Share it on

Saudi J Ophthalmol. 2015 Jul-Sep;29(3):182-6. doi: 10.1016/j.sjopt.2014.12.002. Epub 2014 Dec 13.

Comparison of intravitreal ranibizumab between phakic and pseudophakic neovascular age-related macular degeneration patients: Two-year results.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society

Abdullah Ozkaya, Zeynep Alkin, Ihsan Yilmaz, Ahmet Taylan Yazici

Affiliations

  1. Beyoglu Eye Research and Training Hospital, Beyoglu, Istanbul, Turkey.

PMID: 26155075 PMCID: PMC4487941 DOI: 10.1016/j.sjopt.2014.12.002

Abstract

BACKGROUND AND OBJECTIVE: To compare the efficacy of intravitreal ranibizumab (IVR) for the treatment of neovascular age-related macular degeneration (nAMD) between phakic and pseudophakic eyes after a follow-up of two years.

MATERIALS AND METHODS: Data were analyzed retrospectively. The newly diagnosed and treatment naïve nAMD patients were included in the study. The patients were divided into two subgroups: phakic group, and pseudophakic. All patients received 3 consecutive monthly IVR injections, and then the treatment was continued on an as-needed regimen. Patients were examined monthly, and the data at the baseline, at month 6, 12, 18, and 24 were evaluated. The changes in best corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of injections were compared between the two groups.

RESULTS: The study included 92 eyes of 87 patients (58 phakic, 34 pseudophakic). Mean logarithm of the minimal angle of resolution (LogMAR) VA at the baseline, and at month 6, 12, 18, and 24 was 0.89, 0.74, 0.75, 0.73, and 0.75, in the phakic group; and 0.79, 0.71, 0.66, 0.70, and 0.70 in the pseudophakic group, respectively. The change in mean BCVA from the baseline to month 6, 12, 18, and 24 was not statistically different between the two groups (p = 0.4, p = 0.9, p = 0.5, p = 0.6, respectively). Mean injection number at month 24 was 7.9 and 8.1 in the phakic and pseudophakic group, respectively (p = 0.7).

CONCLUSION: Intravitreal ranibizumab treatment on an as-needed treatment regimen is effective in preserving vision and improving central retinal thickness in both the phakic and pseudophakic group of nAMD patients. The functional and anatomical outcomes of the treatment, and the number of injections were similar in the phakic and pseudophakic nAMD patients after a follow-up time of 24 months.

Keywords: Age-related macular degeneration; Cataract; Lens; Pseudophakia; Ranibizumab; Visual acuity

References

  1. Exp Eye Res. 2005 Mar;80(3):337-47 - PubMed
  2. Retina. 2011 Feb;31(2):393-400 - PubMed
  3. Am J Ophthalmol. 2009 Jul;148(1):43-58.e1 - PubMed
  4. Ophthalmic Surg Lasers Imaging Retina. 2013 Sep-Oct;44(5):471-6 - PubMed
  5. Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):308-15 - PubMed
  6. Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):277-84 - PubMed
  7. N Engl J Med. 2006 Oct 5;355(14 ):1432-44 - PubMed
  8. Ophthalmology. 2013 Jun;120(6):1278-82 - PubMed
  9. Ophthalmology. 2003 Oct;110(10):1960-7 - PubMed
  10. Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):226-8 - PubMed
  11. Exp Eye Res. 1997 Jun;64(6):963-70 - PubMed
  12. Retina. 1992;12(4):305-14 - PubMed
  13. Ophthalmic Surg Lasers Imaging. 2006 Jul-Aug;37(4):272-7 - PubMed
  14. Ophthalmology. 2002 Jun;109(6):1092-7 - PubMed
  15. Retina. 2014 Jan;34(1):32-7 - PubMed
  16. N Engl J Med. 2011 May 19;364(20):1897-908 - PubMed
  17. Br J Ophthalmol. 1994 Jun;78(6):441-5 - PubMed
  18. N Engl J Med. 2006 Oct 5;355(14):1419-31 - PubMed
  19. Ophthalmology. 1996 Oct;103(10):1546-54 - PubMed
  20. Ophthalmology. 2012 Nov;119(11):2298-303 - PubMed
  21. Invest Ophthalmol Vis Sci. 2000 Nov;41(12):3984-90 - PubMed
  22. Arch Ophthalmol. 1984 Nov;102(11):1640-2 - PubMed
  23. Ophthalmic Surg Lasers Imaging Retina. 2013 May-Jun;44(3):225-6 - PubMed
  24. Retina. 2013 Mar;33(3):467-73 - PubMed
  25. J Fr Ophtalmol. 2009 Jun;32(6):440-51 - PubMed
  26. Eye (Lond). 2009 Jun;23 (6):1388-92 - PubMed
  27. Arch Ophthalmol. 1998 Apr;116(4):506-13 - PubMed
  28. Retina. 2014 May;34(5):853-9 - PubMed
  29. Acta Ophthalmol Scand. 2006 Feb;84(1):4-15 - PubMed

Publication Types